Sridhar Mishra1, Vandna Tiwari1, Aditi Arora1, Seema Gupta2, Nidhi Anand2, Nuzhat Husain1. 1. Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. 2. Department of Radiotherapy, King George Medical University, Lucknow, Uttar Pradesh, India.
Abstract
BACKGROUND: Current study investigates the role of Oct4, Nanog and CD24 in locally-advanced oral squamous cell carcinoma (OSCC), to evaluate whether the expression of these markers can predict efficacy of neoadjuvant-chemo-radiotherapy and survival of patients. METHODS: Biomarker expression was evaluated in 50 homogenously treated patients of locally-advanced OSCC. RESULTS: Clinical response was complete in 30% (n=15), partial response in 46% (n=23), no response in 24% (n=12). Pathologically, 74% patents (n=37) were responders and 26% were non-responders (n=13). Biomarker-overexpression was seen in 46% cases for Oct4, 54% cases for Nanog and 58% cases for CD24. Oct4, Nanog and CD24 expression showed significant correlation with clinical and pathological response (p <0.05). Three year recurrence-free survival was 71%, overall survival was 66%. Post-treatment advanced pathological N (ypN), post treatment advanced pathological TNM (ypTNM) stage, clinical non-response, pathologic non-response, positive/high expression of all three biomarkers had a significant negative impact on recurrence-free and overall survival. CONCLUSIONS: Expressions of Oct4, Nanog and CD24 have significant association with treatment response and survival in patients with locally advanced OSCC treated with neoadjuvant chemo-radiation. Survival of these patients is significantly affected by ypN stage, ypTNM stage, expression of all three biomarkers, clinical and pathological response to neoadjuvant therapy.<br />.
BACKGROUND: Current study investigates the role of Oct4, Nanog and CD24 in locally-advanced oral squamous cell carcinoma (OSCC), to evaluate whether the expression of these markers can predict efficacy of neoadjuvant-chemo-radiotherapy and survival of patients. METHODS: Biomarker expression was evaluated in 50 homogenously treated patients of locally-advanced OSCC. RESULTS: Clinical response was complete in 30% (n=15), partial response in 46% (n=23), no response in 24% (n=12). Pathologically, 74% patents (n=37) were responders and 26% were non-responders (n=13). Biomarker-overexpression was seen in 46% cases for Oct4, 54% cases for Nanog and 58% cases for CD24. Oct4, Nanog and CD24 expression showed significant correlation with clinical and pathological response (p <0.05). Three year recurrence-free survival was 71%, overall survival was 66%. Post-treatment advanced pathological N (ypN), post treatment advanced pathological TNM (ypTNM) stage, clinical non-response, pathologic non-response, positive/high expression of all three biomarkers had a significant negative impact on recurrence-free and overall survival. CONCLUSIONS: Expressions of Oct4, Nanog and CD24 have significant association with treatment response and survival in patients with locally advanced OSCC treated with neoadjuvant chemo-radiation. Survival of these patients is significantly affected by ypN stage, ypTNM stage, expression of all three biomarkers, clinical and pathological response to neoadjuvant therapy.<br />.
Authors: T Kirita; Y Yamanaka; Y Imai; N Yamakawa; K Aoki; Y Nakagawa; T Yagyuu; M Hasegawa Journal: Int J Oral Maxillofac Surg Date: 2012-02-21 Impact factor: 2.789
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Oliver Driemel; Tobias Ettl; Oliver Kölbl; Torsten E Reichert; Bernd V Dresp; Jürgen Reuther; Hans Pistner Journal: Strahlenther Onkol Date: 2009-05-15 Impact factor: 3.621
Authors: Glen Kristiansen; Klaus-Jürgen Winzer; Empar Mayordomo; Joachim Bellach; Karsten Schlüns; Carsten Denkert; Edgar Dahl; Christian Pilarsky; Peter Altevogt; Hans Guski; Manfred Dietel Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531